The 2 Minute Medicine Podcast Episode 15
Welcome to the 2 Minute Medicine Podcast, summarizing the latest medical studies, curated and written by practicing physicians. On this ...
Tag: ovarian cancer
![ABCD2 Score: Predicting Early Stroke Risk After Transient Ischemic Attack (TIA) [Classics Series]](https://www.2minutemedicine.com/wp-content/uploads/2013/05/web-cover-classics-with-logo-medicine-BW-small-jpg-350x250.jpg){kind=logo}
Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]
This study summary is an excerpt from the book 2 Minute Medicine's The Classics in Medicine: Summaries of the Landmark ...
Ovarian cancer screening does not reduce mortality [Classics Series]
This study summary is an excerpt from the book 2 Minute Medicine's The Classics in Medicine: Summaries of the Landmark ...
MRI enhances diagnostic certainty of ovarian cancer following indeterminate ultrasound [Classics Series]
This study summary is an excerpt from the book 2 Minute Medicine's The Classics in Medicine: Summaries of the Landmark ...
Apatinib plus pegylated liposomal doxorubicin as an alternative treatment option in platinum-resistant ovarian cancer
1. Apatinib plus pegylated liposomal doxorubicin led to longer overall survival and progression-free survival, and a higher objective response rate ...
Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]
This study summary is an excerpt from the book 2 Minute Medicine's The Classics in Medicine: Summaries of the Landmark ...
Rucaparib compared to standard-of-care chemotherapy showed promising clinical and safe response to treat BRCA1 or BRCA2 mutated, relapsed ovarian carcinoma
1. The median progression-free survival was 7.4 months in the rucaparib group and 5.7 months in the chemotherapy group for ...
Trametinib improves progression-free survival among patients with low-grade serous ovarian carcinoma
1. The median progression-free survival for trametinib was significantly greater than that for standard-of-care therapy (13 months vs. 7.2 months). ...
#VisualAbstract: Annual screening for ovarian cancer does not significantly reduce mortality
1. Both CA125 serum and transvaginal ultrasound annual screening did not significantly reduce deaths due to ovarian or tubal cancer ...
Annual screening for ovarian cancer does not significantly reduce mortality
1. Both CA125 serum and transvaginal ultrasound annual screening did not significantly reduce deaths due to ovarian or tubal cancer ...
